Mostrar el registro sencillo del ítem

The effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label study

dc.creatorHerrera-Estrella, M.
dc.creatorApiquian, R.
dc.creatorFresan, A.
dc.creatorSanchez-Torres, I.
dc.date.accessioned2017-06-29T04:35:48Z
dc.date.available2017-06-29T04:35:48Z
dc.date.issued2005es_ES
dc.identifier460es_ES
dc.identifier.issn1471-244Xes_ES
dc.identifier.urihttp://repositorio.inprf.gob.mx/handle/123456789/5149
dc.identifier.urihttps://doi.org/10.1186/1471-244X-5-22es_ES
dc.identifier.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1090597/es_ES
dc.language.isoenges_ES
dc.relation3 (5) 22 p.es_ES
dc.relationversión del editores_ES
dc.rightsacceso cerradoes_ES
dc.titleThe effects of amisulpride on five dimensions of psychopathology in patients with schizophrenia: a prospective open-label studyes_ES
dc.typearticlees_ES
dc.contributor.affiliationPsychiatry Department, National Institute of Neurology and Neurosurgery, Mexico Cityes_ES
dc.contributor.emailMdmiguelherrera@aol.comes_ES
dc.relation.jnabreviadoBMC PSYCHIATRYes_ES
dc.relation.journalBMC Psychiatryes_ES
dc.identifier.placeInglaterraes_ES
dc.date.published2005es_ES
dc.identifier.organizacionInstituto Nacional de Psiquiatría Ramón de la Fuente Muñizes_ES
dc.description.monthMayes_ES
dc.description.abstractotrodiomaBACKGROUND: The efficacy of antipsychotics can be evaluated using the dimensional models of schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and tolerability to other atypical antipsychotics. The aim of the present study was to determine the efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin schizophrenic patients. METHOD: Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label 3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and side-effects were evaluated with standardized scales. RESULTS: The patients showed significant improvement in the five dimensions evaluated. Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent extrapyramidal side-effects. CONCLUSION: Amisulpride showed efficacy on different psychopathological dimensions and was well tolerated, leading to consider this drug a first line choice for the treatment of schizophreniaes_ES


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem